Preclinical and clinical studies support a role for SGLT2 inhibitors in retarding blood vessel stenosis following arterial injury and alleviating the maladaptive remodeling of pulmonary arterioles in pulmonary arterial hypertension. The gene discussed is SLC5A2; the disease is pulmonary arterial hypertension.